Included within weighted average shares of common stock outstanding for the three and nine months ended September 30, 2026 are 36,923 and 54,366 shares of common stock issuable upon the exercise of nominal exercise price warrants, respectively. Included within weighted average shares of common stock outstanding for the three and nine months ended September 30, 2025 are 113,873 and 113,960 shares of common stock issuable upon the exercise of nominal exercise price warrants, respectively. Additionally, included within weighted average common shares outstanding for the three and nine months ended September 30, 2026 are 1,907,078 and 1,395,354 shares of common stock issuable upon the exercise of pre-funded warrants issued in connection with the Company’s February 2026 and July 2026 private placements at an exercise price of $0.0001 per share. The pre-funded warrants are exercisable at any time for nominal consideration and are therefore included in basic and diluted weighted average shares outstanding from the date of issuance. Per ASC 260, Earnings Per Share, the warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.